ArticleJournal of neuro-oncology2018
Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma.
Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Exogenous Hormones and Their Clinical Implications for the Development and Growth of Meningioma Tumours.Journal of clinical medicine · 2026Review
- Progestogen use and the risk of intracranial meningioma: a systematic review and meta-analysis.EClinicalMedicine · 2026Article
- Hormonal contraceptives and the risk of meningioma: A Swedish register-based case-control study.Neuro-oncology · 2026Article
- Risk of intracranial meningioma requiring surgical intervention among recent hormonal contraceptives users.Journal of neuro-oncology · 2026Article
- MRI-based deep transfer learning models for predicting progesterone receptor expression in meningioma.Frontiers in oncology · 2025Article
- Regression of multiple intracranial meningiomas after cessation of long-term synthetic progesterone (megestrol) medication: case report and autopsy.Free neuropathology · 2024Article
- Association of Hormonal Contraception with Meningioma Location in Indonesian Patients.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- A decreased risk of meningioma in women smokers was only observed in American studies rather than studies conducted in other countries: a systematic review and meta-analysis.Chinese neurosurgical journal · 2021Article
- Regression of Multiple Meningiomas after Discontinuation of Chronic Hormone Therapy: A Case Report.Journal of neurological surgery reports · 2021Article
- Progesterone Receptor Expression in Meningiomas: Pathological and Prognostic Implications.Frontiers in oncology · 2021Article
- Female gender and exogenous progesterone exposition as risk factors for spheno-orbital meningiomas.Journal of neuro-oncology · 2020Article
- Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.Pathology oncology research : POR · 2020Review
- Meningiomas in Premenopausal Women: Role of the Hormone Related Conditions.Frontiers in oncology · 2020Article
- Fertility treatment is associated with multiple meningiomas and younger age at diagnosis.Journal of neuro-oncology · 2019Article
- Relationships Between Neurofibromatosis-2, Progesterone Receptor Expression, the Use of Exogenous Progesterone, and Risk of Orbitocranial Meningioma in Females.Frontiers in oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hormonally active nature of intracranial meningioma has prompted research examining the risk of tumorigenesis in patients using hormonal contraception. Studies exploring estrogen-only and estrogen/progesterone combination contraceptives have failed to demonstrate a consistent increased risk of meningioma. By contrast, the few trials examining progesterone-only contraceptives have shown higher odds ratios for risk of meningioma. With progesterone-only contraception on the rise, the risk of tumor recurrence with these specific medications warrants closer study. We sought to determine whether progesterone-only contraception increases recurrence rate and decreases progression-free survival in pre-menopausal women with surgically resected WHO Grade I meningioma. Comparative analysis of 67 pre-menopausal women taking hormone-based contraceptives (progesterone-only medication, n = 21; estrogen-only or estrogen/progesterone combination medication, n = 46) who underwent surgical resection of WHO Grade I intracranial meningioma was performed. Differences in demographics, degree of resection, adjuvant therapy and time to recurrence were compared between the two groups. Compared to patients taking combination or estrogen-only contraception, those taking progesterone-only contraception demonstrated a greater recurrence rate (33.3 vs. 19.6%) with a reduced time to recurrence (18 vs. 32 months, p = 0.038) despite a significantly shorter follow-up (p = 0.014). There were no significant demographic or treatment related differences. The results from this study suggest that exogenous progesterone-only medications may represent a specific contraceptive subgroup that should be avoided in patients with meningioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.